Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFIRINOX and Concurrent Capecitabine-RT for Locally Advanced Pancreatic Cancer
NCT02311439Phase 3Unknown
- Sponsor
- Assiut University
- Start
- Oct 2014
- Primary completion
- Nov 2016
- Modality
- Nanoparticles, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of oxaliplatin, irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab, fluorouracil, folinic acid and capecitabine in pancreatic cancer (PC), sponsored by Assiut University. Primary endpoint: Number of Participants with Adverse Events as a Measure of Safety and Tolerability at 6 months. Status: unknown.
02
Drugs
oxaliplatinirinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumabfluorouracilfolinic acidcapecitabine
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT02311439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02311439.